Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Roberto Stasi, MD, PhD, Adrian Newland, Bertrand Godeau, Victor Priego, MD, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Catherine Jia, Angela Lopez

Blood (2013) 122 (21): 1074.

https://doi.org/10.1182/blood.V122.21.1074.1074

Published: 2013

Journal Articles

Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,

James B Bussel, MD, Francesco Rodeghiero, MD, Roger M. Lyons, MD, Barry Firstenberg, Joanne Joseph, Craig M. Kessler, MD, Louis Terriou, Roberto Stasi, MD, PhD, Paul Chang, Susie Jun

Blood (2011) 118 (21): 3281.

https://doi.org/10.1182/blood.V118.21.3281.3281

Published: 2011

Journal Articles

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Vivek L. Patel, MS, Matthieu Mahévas, MD, Roberto Stasi, MD, Susanna Cunningham-Rundles, PhD, Bertrand Godeau, MD, Soo Y. Lee, BS, Julie Kanter, MD, Ellis J. Neufeld, MD, PhD, Tillmann Taube, MD, Ugo Ramenghi, MD, Shalini Shenoy, MD, Mary J. Ward, PhD, Nino Mihatov, BS, Vinay L. Patel, BS, Philippe Bierling, MD, Nichola Cooper, MD, James B. Bussel, MD

Blood (2010) 116 (21): 72.

https://doi.org/10.1182/blood.V116.21.72.72

Published: 2010

Journal Articles

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.

Roberto Stasi, MD, Magaral Murali, Marc Michel, Jean-Francois Viallard, MD, PhD, Aristoteles Giagounidis, Ann Janssens, MD, Jason Legg, Mark Danese, Robert Deuson, PhD

Blood (2009) 114 (22): 1311.

https://doi.org/10.1182/blood.V114.22.1311.1311

Published: 2009

Journal Articles

The Efficacy of H. pylori Eradication Therapy in H. pylori -Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic Review.

Donald M. Arnold, MD, Ashley Bernotas, Ishac Nazi, PhD, Roberto Stasi, MD, Masataka Kuwana, MD, PhD, John G. Kelton, MD, FRCPC, Mark A. Crowther, MD

Blood (2008) 112 (11): 3413.

https://doi.org/10.1182/blood.V112.11.3413.3413

Published: 2008

Journal Articles

Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.

Vivek Patel, BS, Nino Mihatov, Nichola Cooper, MD, Roberto Stasi, MD, Susanna Cunningham-Rundles, PhD, James B. Bussel, MD

Blood (2006) 108 (11): 479.

https://doi.org/10.1182/blood.V108.11.479.479

Published: 2006

NARROW

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.

The Efficacy of H. pylori Eradication Therapy in H. pylori -Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic Review.

Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.

Email alerts

ASH Publications

American Society of Hematology

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,

Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)

Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.

The Efficacy of H. pylori Eradication Therapy in H. pylori -Infected and Uninfected Patients with Immune Thrombocytopenic Purpura: A Systematic Review.

Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only